{"success":true,"data":{"pressRelease":{"id":"48261","rtpr_id":"nGNE6rmZs5","ticker":"PMN","exchange":"NASDAQ","all_tickers":["PMN"],"title":"ProMIS Neurosciences to Participate in Upcoming Conferences in June","author":"Globe Newswire","published_at":"2026-05-28T14:13:28.216Z","article_body":"CAMBRIDGE, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc.\n(Nasdaq: PMN), a clinical-stage biotechnology company developing antibody\ntherapeutics and vaccines targeting toxic misfolded proteins in\nneurodegenerative diseases, today announced that it will participate in\nupcoming June 2026 conferences, and will be available for one-on-one meetings.\n\nConference details below:\n\nJefferies Global Healthcare Conference, June 2-4, 2026\nLocation: New York, NY\nPresentation: Thursday, June 4, 2026, from 11:40 a.m. to 12:10 p.m. ET\nWebcast link: Click here\n(https://www.globenewswire.com/Tracker?data=xfCbO07FOhL4jSN9U9gqwf_8C5qveukNWAeErUqb5j4elibKawS8uPkfKywAiaw0TKLjbAZs3XcOC631PeH97KBKtwuiusFRF7N4CyRDrCpNljgPsgLH-CtL5yUAp4LIUOCSTJpEmoguYRam1Uvz7A==).\n\nVirtual Alzheimer’s R&D Day, organized by Wolfe Research, June 4, 2026\nPresentation: Thursday, June 4, 2026, from 8:30 a.m. to 9:00 a.m. ET\n(invitation-only)\nThe event will feature leading companies and key opinion leaders in\nAlzheimer’s disease research, discussing the current treatment landscape,\ndevelopment of disease modifying therapies and symptom management.\n\nOppenheimer CNS Summit, June 10, 2026\nLocation: Miami, FL\nOne-on-one meetings only\n\nH.C. Wainwright Neuro Perspectives Expert Summit, June 15-16, 2026\nLocation: New York, NY\nPresentation: Monday, June 15, 2026\n\nBIO International Convention, June 22-25, 2026\nLocation: San Diego, CA\nOne-on-one meetings only\n\nDuring these conferences, Neil Warma, CEO of ProMIS Neurosciences, will\ndiscuss the Company’s EpiSelect™ platform and differentiated approach to\ndeveloping therapeutics for neurodegenerative diseases driven by toxic\nmisfolded proteins, including its lead Alzheimer’s disease (AD) candidate,\nPMN310.\n\nPMN310 is designed to selectively target toxic amyloid-beta oligomers believed\nto drive AD pathology while avoiding plaque binding, an approach intended to\npotentially reduce off-target effects associated with plaque-directed\ntherapies.\n\nProMIS expects to report blinded 6-month interim data from its fully enrolled\nPRECISE-AD Phase 1b trial in patients with early AD in early Q3 2026, with\n12-month topline data anticipated in early 2027.\n\nWebcast replays of the presentations will be available in the Investors\nsection of the ProMIS Neurosciences website at\nhttps://www.promisneurosciences.com/ under “News & Events”.\n\nAbout ProMIS Neurosciences Inc.\nProMIS Neurosciences is a clinical-stage biotechnology company committed to\nthe discovery and development of therapeutic antibodies and vaccines selective\nfor toxic oligomers associated with the development and progression of\nneurodegenerative and other misfolded protein diseases. The Company’s\nproprietary target discovery engine, EpiSelect™, has been shown to predict\nnovel targets known as Disease Specific Epitopes (DSEs) on the molecular\nsurface of misfolded proteins that cause neurodegenerative and other misfolded\nprotein diseases, including Alzheimer’s disease (AD), amyotrophic lateral\nsclerosis (ALS), frontotemporal dementia (FTD), multiple system atrophy (MSA),\nand Parkinson’s Disease (PD). ProMIS has offices in Cambridge, Massachusetts\n(USA) and Toronto, Ontario (CAN).\n\nForward-looking Statements\nThis press release contains forward-looking statements that are made pursuant\nto the safe harbor provisions of the Private Securities Litigation Reform Act\nof 1995. Certain information in this news release constitutes forward-looking\nstatements and forward-looking information within the meaning of applicable\nsecurities laws. In some cases, but not necessarily in all cases,\nforward-looking information can be identified by the ‎use of forward-looking\nterminology such as “plans”, “expects”, “anticipates”,\n“believes”, or variations of such words and ‎phrases. Specifically, this\nnews release contains forward-looking information relating to the Company’s\nPhase 1b study in AD patients, including planned timing for completion and\nanticipated data read out of interim results expected in early third quarter\nof 2026 and topline results by early 2027, statements relating to the\nCompany's progress, including enrollment and dosing, the potential for PMN310\nto positively benefit patients with AD, the targeting of toxic misfolded\nproteins, and the ability of the Company’s cash runway to fund operations\nthrough 2027. Forward-looking information is necessarily based on a number of\nopinions, assumptions and estimates that, while considered reasonable by the\nCompany as of the date of this news release, are subject to ‎known and\nunknown risks and uncertainties, including the risk that preclinical results\nor early results may not be indicative of future results. Except as required\nby applicable securities laws, the Company undertakes no obligation to\npublicly update any forward-looking information.\n\nInvestor Relations Contact:\nCarie Pierce VP, Investor Relations & External Affairs\nIR@promisneurosciences.com","article_body_html":"","raw_payload":{"data":{"id":"nGNE6rmZs5","title":"ProMIS Neurosciences to Participate in Upcoming Conferences in June","author":"Globe Newswire","ticker":"PMN","created":"2026-05-28T14:13:28.216Z","tickers":["PMN"],"exchange":"NASDAQ","article_body":"CAMBRIDGE, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc.\n(Nasdaq: PMN), a clinical-stage biotechnology company developing antibody\ntherapeutics and vaccines targeting toxic misfolded proteins in\nneurodegenerative diseases, today announced that it will participate in\nupcoming June 2026 conferences, and will be available for one-on-one meetings.\n\nConference details below:\n\nJefferies Global Healthcare Conference, June 2-4, 2026\nLocation: New York, NY\nPresentation: Thursday, June 4, 2026, from 11:40 a.m. to 12:10 p.m. ET\nWebcast link: Click here\n(https://www.globenewswire.com/Tracker?data=xfCbO07FOhL4jSN9U9gqwf_8C5qveukNWAeErUqb5j4elibKawS8uPkfKywAiaw0TKLjbAZs3XcOC631PeH97KBKtwuiusFRF7N4CyRDrCpNljgPsgLH-CtL5yUAp4LIUOCSTJpEmoguYRam1Uvz7A==).\n\nVirtual Alzheimer’s R&D Day, organized by Wolfe Research, June 4, 2026\nPresentation: Thursday, June 4, 2026, from 8:30 a.m. to 9:00 a.m. ET\n(invitation-only)\nThe event will feature leading companies and key opinion leaders in\nAlzheimer’s disease research, discussing the current treatment landscape,\ndevelopment of disease modifying therapies and symptom management.\n\nOppenheimer CNS Summit, June 10, 2026\nLocation: Miami, FL\nOne-on-one meetings only\n\nH.C. Wainwright Neuro Perspectives Expert Summit, June 15-16, 2026\nLocation: New York, NY\nPresentation: Monday, June 15, 2026\n\nBIO International Convention, June 22-25, 2026\nLocation: San Diego, CA\nOne-on-one meetings only\n\nDuring these conferences, Neil Warma, CEO of ProMIS Neurosciences, will\ndiscuss the Company’s EpiSelect™ platform and differentiated approach to\ndeveloping therapeutics for neurodegenerative diseases driven by toxic\nmisfolded proteins, including its lead Alzheimer’s disease (AD) candidate,\nPMN310.\n\nPMN310 is designed to selectively target toxic amyloid-beta oligomers believed\nto drive AD pathology while avoiding plaque binding, an approach intended to\npotentially reduce off-target effects associated with plaque-directed\ntherapies.\n\nProMIS expects to report blinded 6-month interim data from its fully enrolled\nPRECISE-AD Phase 1b trial in patients with early AD in early Q3 2026, with\n12-month topline data anticipated in early 2027.\n\nWebcast replays of the presentations will be available in the Investors\nsection of the ProMIS Neurosciences website at\nhttps://www.promisneurosciences.com/ under “News & Events”.\n\nAbout ProMIS Neurosciences Inc.\nProMIS Neurosciences is a clinical-stage biotechnology company committed to\nthe discovery and development of therapeutic antibodies and vaccines selective\nfor toxic oligomers associated with the development and progression of\nneurodegenerative and other misfolded protein diseases. The Company’s\nproprietary target discovery engine, EpiSelect™, has been shown to predict\nnovel targets known as Disease Specific Epitopes (DSEs) on the molecular\nsurface of misfolded proteins that cause neurodegenerative and other misfolded\nprotein diseases, including Alzheimer’s disease (AD), amyotrophic lateral\nsclerosis (ALS), frontotemporal dementia (FTD), multiple system atrophy (MSA),\nand Parkinson’s Disease (PD). ProMIS has offices in Cambridge, Massachusetts\n(USA) and Toronto, Ontario (CAN).\n\nForward-looking Statements\nThis press release contains forward-looking statements that are made pursuant\nto the safe harbor provisions of the Private Securities Litigation Reform Act\nof 1995. Certain information in this news release constitutes forward-looking\nstatements and forward-looking information within the meaning of applicable\nsecurities laws. In some cases, but not necessarily in all cases,\nforward-looking information can be identified by the ‎use of forward-looking\nterminology such as “plans”, “expects”, “anticipates”,\n“believes”, or variations of such words and ‎phrases. Specifically, this\nnews release contains forward-looking information relating to the Company’s\nPhase 1b study in AD patients, including planned timing for completion and\nanticipated data read out of interim results expected in early third quarter\nof 2026 and topline results by early 2027, statements relating to the\nCompany's progress, including enrollment and dosing, the potential for PMN310\nto positively benefit patients with AD, the targeting of toxic misfolded\nproteins, and the ability of the Company’s cash runway to fund operations\nthrough 2027. Forward-looking information is necessarily based on a number of\nopinions, assumptions and estimates that, while considered reasonable by the\nCompany as of the date of this news release, are subject to ‎known and\nunknown risks and uncertainties, including the risk that preclinical results\nor early results may not be indicative of future results. Except as required\nby applicable securities laws, the Company undertakes no obligation to\npublicly update any forward-looking information.\n\nInvestor Relations Contact:\nCarie Pierce VP, Investor Relations & External Affairs\nIR@promisneurosciences.com"},"type":"article","timestamp":"2026-05-28T14:13:28.307142837Z","server_sent_at_ms":1779977608307},"received_at":"2026-05-28T14:13:28.359Z","source_url":null},"analysis":{"id":"37694","press_release_id":"48261","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"operations_update","narrative":"ProMIS Neurosciences will participate in several major healthcare conferences in June 2026, including presentations at the Jefferies Global Healthcare Conference and Wolfe Research’s Virtual Alzheimer’s R&D Day.\n\nCEO Neil Warma will discuss the company’s EpiSelect platform and lead Alzheimer’s candidate PMN310, which targets toxic amyloid-beta oligomers.\n\nThe company reiterated its timeline to report blinded 6-month interim data from the PRECISE-AD Phase 1b trial in early Q3 2026, with 12-month topline data expected in early 2027.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Routine conference calendar update; no new data or material catalysts."},"keyFigures":{},"quotedText":"ProMIS expects to report blinded 6-month interim data from its fully enrolled PRECISE-AD Phase 1b trial in patients with early AD in early Q3 2026, with 12-month topline data anticipated in early 2027.","namedEntities":{"people":[{"name":"Neil Warma","role":"CEO"},{"name":"Carie Pierce","role":"VP, Investor Relations & External Affairs"}],"products":["EpiSelect","PMN310"],"companies":[{"name":"ProMIS Neurosciences Inc.","ticker":"PMN"},{"name":"Jefferies","relationship":"conference organizer"},{"name":"Wolfe Research","relationship":"conference organizer"},{"name":"Oppenheimer","relationship":"conference organizer"},{"name":"H.C. Wainwright","relationship":"conference organizer"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Routine conference participation announcement with no new clinical data, partnership, or financial disclosure. The mention of upcoming data readouts (Q3 2026) is forward-looking context, not a new event."},"tickerRelevance":{"others":[],"primary":"PMN"},"globalImportance":15,"audienceRelevance":20,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"conference_participation","sectorWeight":"biotech","householdBrandBoost":0,"marketCapAdjustment":"low","retailFavoriteBoost":0}},"event_type":"operations_update","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"ProMIS Neurosciences will participate in several major healthcare conferences in June 2026, including presentations at the Jefferies Global Healthcare Conference and Wolfe Research’s Virtual Alzheimer’s R&D Day.\n\nCEO Neil Warma will discuss the company’s EpiSelect platform and lead Alzheimer’s candidate PMN310, which targets toxic amyloid-beta oligomers.\n\nThe company reiterated its timeline to report blinded 6-month interim data from the PRECISE-AD Phase 1b trial in early Q3 2026, with 12-month topline data expected in early 2027.","key_figures":{},"named_entities":{"people":[{"name":"Neil Warma","role":"CEO"},{"name":"Carie Pierce","role":"VP, Investor Relations & External Affairs"}],"products":["EpiSelect","PMN310"],"companies":[{"name":"ProMIS Neurosciences Inc.","ticker":"PMN"},{"name":"Jefferies","relationship":"conference organizer"},{"name":"Wolfe Research","relationship":"conference organizer"},{"name":"Oppenheimer","relationship":"conference organizer"},{"name":"H.C. Wainwright","relationship":"conference organizer"}],"dollarAmounts":[]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-05-28T14:13:52.783Z","global_importance":15,"audience_relevance":20,"importance_components":{"tickerTier":"small-cap","eventGravity":"conference_participation","sectorWeight":"biotech","householdBrandBoost":0,"marketCapAdjustment":"low","retailFavoriteBoost":0}},"durationMs":24393,"modelName":"george-droid-qwen-72b"}}